About Us

Support Us

Research Awards
   Award Recipients

   Clinical Network
   Preclinical Screening

News Room

   Learn from the Experts
   Clinical Trials
   Additional Resources

Contact Us

Return to Leadership Home Biography

Max Wallace

Max Wallace is Chief Executive Officer of Accelerate Brain Cancer Cure (ABC2). Prior to joining ABC2, Max was CEO of TheraLogics, an early-stage anti-cancer biopharmaceutical company based on technology developed at the University of North Carolina at Chapel Hill. He previously co-founded and served as President of Trimeris, a public biopharmaceutical company that created and brought to market the world's first entry inhibitor, establishing a new class of drugs for HIV/AIDS and other viral diseases. Max also founded and developed several other biopharmaceutical companies, including Cogent Neuroscience; Sphinx Pharmaceuticals Corporation (now a division of Eli Lilly & Co); and SARCO (now a part of PPD/Pharmaco). He also helped form and serves on the board of directors of Humacyte, a tissue engineering company based on the work of Dr. Laura Niklason of Yale University.

Prior to starting Trimeris in 1993, Max spent 10 years on the staff of Duke University in Durham, North Carolina. He was a founding Investment Director of Duke Management Company, the asset management company for the University, where he developed novel approaches to technology development, commercialization and new business creation. Previously at Duke, he served in the Office of General Counsel, as the University's Medical Center Legal Counsel, and as Duke's Director of Government Relations. Prior to joining the staff at Duke, Max practiced law with the firm of English, McCaughan & O'Bryan in Fort Lauderdale, Florida.

Max has served as President of North Carolina's Council for Entrepreneurial Development (CED) and he co-founded and subsequently served as President of the North Carolina Bioscience Organization (NCBIO), the biotechnology industry's trade organization in North Carolina. He recently served for two years as a Senior Fellow in Leadership and Innovation at the Institute for Emerging Issues at N.C. State University, working on issues of public policy related to economic development and the commercialization of innovative technologies. He has served on the boards of directors of the Emerging Companies Section of the Biotechnology Industry Organization (BIO) and the Kenan Institute of Engineering, Technology and Science and on the Advisory Board for the Whitehead Institute at MIT. He also co-founded Duke University's Program in Non-Profit Management and taught graduate courses in Non-Profit Management at the Terry Sanford Institute of Public Policy at Duke.

He received his Bachelor's degree from Duke University in 1974 and his JD degree from the University of Florida in 1977.

Content copyright © 2009 Accelerate Brain Cancer Cure, Inc.